Xcout IntelMineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Subscribe to see Mineralys Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Mineralys Therapeutics, Inc. at a glance
Mineralys Therapeutics, Inc. is a biotech company headquartered in Radnor, United States. It is publicly listed (MLYS) with a market capitalisation of $2.1B. Xcout tracks 25 named people at Mineralys Therapeutics, Inc., including Jon Congleton (President, Chief Executive Officer & Director). Xcout recorded 501 job postings from Mineralys Therapeutics, Inc. in the last 90 days.
Mineralys Therapeutics, Inc. leadership
- Jon CongletonPresident, Chief Executive Officer & Director
- Adam Scott LevyChief Financial Officer & Secretary
- Adam LevyChief Financial Officer
- James J. Ferguson FACCChief Medical Officer
- Eric J. WarrenChief Commercial Officer
- Eric WarrenChief Commercial Officer
19 more named people on record for Mineralys Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Mineralys Therapeutics, Inc.
Xcout recorded 501 job postings from Mineralys Therapeutics, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Mineralys Therapeutics, Inc.'s hiring signals →
Hiring vs the trend
Based on 167 job postings in the last 8 weeks (10 Aug – 4 Oct 2026), compared with 158 scale-up healthcare companies.
This describes a hiring pattern — how often Mineralys Therapeutics, Inc.’s job postings ask for AI skills, and how that changed against the previous 8 weeks, ranked among its peers. It says nothing about the company’s products or performance.
Signed-in members see the AI-skill share and its change with peer percentiles, role mix, posting momentum and advertised US pay against the market.
Mineralys Therapeutics, Inc. competitors
A few of Mineralys Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company that develops and markets cortisol modulation therapies to treat serious medical conditions. The company focuses on modulating cortisol activity at the glucocorticoid receptor to create novel treatments across therapeutic areas such as endocrinology, oncology, metabolism, and neurology.
Crystalys Therapeutics is a biotechnology research company headquartered in San Diego, California, dedicated to developing novel therapies to address significant unmet medical needs.
ENYO Pharma is a clinical-stage biopharmaceutical company that develops therapeutics for patients with impaired kidney function. Its lead compound, Vonafexor, is a small molecule currently in Phase 2 development to treat rare kidney diseases such as Alport syndrome and chronic kidney disease.
Quantum Genomics was a French biopharmaceutical company focused on developing treatments for cardiovascular diseases, particularly difficult-to-treat or resistant hypertension. Its lead candidate, firibastat, was designed as a brain aminopeptidase A inhibitor for patients whose hypertension is not adequately controlled by existing therapies.
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, with additional operations in San Diego, California. The company focuses on the discovery and development of novel biopharmaceuticals for cardiovascular and other severe diseases.
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company that engages in the development of products to address pulmonary hypertension related to interstitial lung disease.
Get Mineralys Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Mineralys Therapeutics, Inc. in Xcout Intel
- 25 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access